Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: A pooled analysis of 4 randomized, placebo-controlled studies

MeiYun Ke, Jan Tack, Eamonn M M Quigley, Duowu Zou, Suck Chei Choi, Somchai Leelakusolvong, Andy Liu, JinYong Kim

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Background/Aims: To compare the efficacy and safety of prucalopride, a novel selective high-affinity 5-hydroxytryptamine type 4 receptor agonist, versus placebo, in Asian and non-Asian women with chronic constipation (CC). Methods: Data of patients with CC, receiving once-daily prucalopride 2-mg or placebo for 12-weeks, were pooled from 4 double-blind, randomized, phase-III trials (NCT00488137, NCT00483886, NCT00485940 and NCT01116206). The efficacy endpoints were: average of ≥ 3 spontaneous complete bowel movements (SCBMs)/week; average increases of ≥ 1 SCBMs/week; and change from baseline in each CC-associated symptom scores (bloating, abdominal pain, hard stool and straining). Results: Overall, 1,596 women (Asian [26.6%], non-Asian [73.4%]) were included in this analysis. Significantly more patients in the prucalopride group versus placebo experienced an average of ≥ 3 SCBMs/week in Asian (34% vs. 11%, P < 0.001) and non-Asian (24.6% vs. 10.6%, P < 0.001) subgroups. The number of patients reporting an increase of ≥ 1 SCBMs/week from baseline was significantly higher in the prucalopride group versus placebo among both Asian (57.4% vs. 28.3%, P < 0.001) and non-Asian (45.3% vs. 24.0%, P < 0.001) subgroups. The difference between the subgroups was not statistically significant. Prucalopride significantly reduced the symptom scores for bloating, hard stool, and straining in both subgroups. Conclusions: Prucalopride 2-mg once-daily treatment over 12-weeks was more efficacious than placebo in promoting SCBMs and improvement of CC-associated symptoms in Asian and non-Asian women, and was found to be safe and well-tolerated. There were numeric differences between Asian and non-Asian patients on efficacy and treatment emergent adverse events, which may be partially due to the overlap with functional gastrointestinal disorders in non-Asian patients.

Original languageEnglish (US)
Pages (from-to)458-468
Number of pages11
JournalJournal of Neurogastroenterology and Motility
Volume20
Issue number4
DOIs
StatePublished - 2014

Keywords

  • Asian women
  • Chronic constipation
  • Non-Asian women
  • Prucalopride
  • Serotonin 5-HT receptor agonists

ASJC Scopus subject areas

  • Gastroenterology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Effect of prucalopride in the treatment of chronic constipation in Asian and non-Asian women: A pooled analysis of 4 randomized, placebo-controlled studies'. Together they form a unique fingerprint.

Cite this